Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids.

By B. Alger. Progress in neurobiology, 2002

595 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Cognitive Neuroscience, Pharmacology

View Paper: https://www.semanticscholar.org/paper/24bd478137fe2ffa484a854d88a2af307300c71b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. P. Pacher
2. S. Batkai
3. P. Castillo
4. George Kunos
5. Y. Hashimotodani
6. Allyn C. Howlett
7. Daniele Piomelli
8. Wickliffe C. Abraham

In Cognitive Neuroscience

1. P. Castillo
2. Daniele Piomelli
3. Wickliffe C. Abraham
4. George Kunos

In Pharmacology

1. P. Pacher
2. S. Batkai
3. George Kunos
4. P. Castillo
5. Y. Hashimotodani
6. G. Marsicano
7. B. Lutz
8. Allyn C. Howlett

Citations in the corpus

• Metaplasticity: tuning synapses and networks for plasticity (2008, background): “These receptors are activated by endogenous endocannabinoids that serve as retrograde signals following postsynaptic group-1 mGluR activation and membrane depolarizatio”
• The emerging role of the endocannabinoid system in endocrine regulation and energy balance. (2006, background): “They thus mediate a retrograde signal (30, 106, 107).”
• The molecular logic of endocannabinoid signalling (2003, background): “This phenomenon, called depolarization-induced suppression of inhibition (DSI), is initiated postsynaptically by voltage-dependent influx of Ca 2+ into the soma and dendrites of the neuron, but is expressed presynaptically through inhibition of transmitter release from axon terminals of GABA intern”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…retrogradely to modulate both inhibitory GABAergic and excitatory glutamatergic transmissions via multiple mechanisms (Marsicano and Lutz, 1999; Alger, 2002, 2004; Gerdeman et al., 2002; Robbe et al., 2002; Azad et al., 2003; Freund et al., 2003; Gerdeman and Lovinger, 2003; Kim and Alger,…”
• Endocannabinoid signaling and synaptic function (2012, background): “Review and GABA, CB 1 Rs can also control the release of several neuromodulators including serotonin, acetylcholine, dopamine, opioids, norepinephrine, and cholecystokinin (Alger, 2002; Kano et al., 2009; Schlicker and Kathmann, 2001).”
• Cannabinoid physiology and pharmacology: 30 years of progress. (2004, background): “Endocannabinoid compounds diffuse from the post-synaptic membrane and bind to CB 1 receptors on presynaptic terminals of a subclass of interneurons, where they inhibit release of GABA (Alger, 2002).”
• The endocannabinoid system controls key epileptogenic circuits in the hippocampus. (2006, unknown): “…but Are Dispensable for Pharmacological GABA-Mediated Protection against KA-Induced Seizures As CB1 receptors are well known to control GABAergic transmission (Chevaleyre et al., 2006; Alger, 2002; Freund et al., 2003), the absence of a phenotype in GABA-CB1−/− mice is a surprising result.”